Transforming growth factor-β in in vivo resistance

Cancer Chemotherapy and Pharmacology

Volumn 37, Issue 6, 1996, Pages 601-609

  Teicher, Beverly A ^a   Holden, Sylvia A ^a   Ara, Gulshan ^a   Chen, Guan ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cisplatin resistance; Cyclophosphamide resistance; Drug resistance; In vivo resistance; Transforming growth factor

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 REDUCTASE; GLUCOSE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; LACTIC ACID; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; BONE MARROW TOXICITY; BREAST CARCINOMA; CANCER GRAFT; CELL SURVIVAL; COLONY FORMING UNIT GM; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW CELLS; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; FEMALE; GLUTATHIONE; HEMATOPOIESIS; LIVER; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; TRANSFORMING GROWTH FACTOR BETA;

EID: 0029873924     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050435     Document Type: Article

References (34)

1. Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A, Frei E III (1986) Alkylating agents: in vitro studies of cross-resistance patterns. Cancer Res 46: 4379.
2. Teicher BA, Holden SA, Kelley MJ, Shea TC, Cucchi CA, Rosowsky A, Henner WD, Frei E III (1987) Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res 47: 388
3. Teicher BA, Holden SA, Cucchi CA, Cathcart KNS, Korbut TT, Flatow JL, Frei E III (1988) Combination of N,N′,N″-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res 48: 94
4. Teicher BA (ed) (1993) Mechanisms of reistance in oncology. Dekker, New York
5. Teicher BA, Frei E III (1988) Development of alkylating agent resistant human tumor cell lines. Cancer Chemother Pharmacol 21: 292
6. Teicher BA, Holden SA, Herman TS, Alvarez Sotomayor E, Khandekar V, Rosbe KW, Brann TW, Korbut TT, Frei E III (1991) Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II) Int J Cancer 47: 252
7. Frei E III, Teicher BA, Holden SA, Cathcart KNS, Wang Y (1988) Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 48: 6417
8. Frei E III, Teicher BA, Cucchi CA, Rosowsky A, Flatow JL, Kelley MJ, Genereux P (1988) Resistance to alkylating agents: basic studies and therapeutic implications. In: Woolley PVI, Tew KD (eds) Mechanisms of drug resistance in neoplastic cells. Academic Press, New York, p 69
9. Teicher BA, Herman TS, Holden SA, Wang Y, Pfeffer MR, Crawford JM, Frei E III (1990) Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247: 1457
10. Teicher BA, Chatterjee D, Liu J-T, Holden SA, Ara G (1993) Protection of bone-marrow granulocyte-macrophage colony-forming units in mice bearing in vivo alkylating-agent-resistant EMT-6 tumors. Cancer Chemother Pharmacol 32: 315.
11. Chatterjee D, Liu CI-T, Northey D, Teicher BA (1995) Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors. Cancer Chemother Pharmacol 35: 4230
12. Teicher BA, Holden SA, Jacobs JL (1987) Approaches to denning the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res 47: 513
13. Griffith OW (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106: 207
14. Habig WH, Jakoby WB (1981) Assays for differentiation of glutathione-S-transferase. Methods Enzymol 77: 398
15. Goldberg D, Spooner RJ (1982) Glutathione reductase. In: Bergmeyer HU (ed) Methods of enzymatic analysis. Verlag Chemie, Weinheim, p 258
16. Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 158
17. Waxman DJ, Walsh C (1982) Phenobarbital-induced rat cytochrome P450. J Biol Chem 257: 10446
18. Border WA, Noble NA (1994) Transforming growth factor β in tissue fibrosis. N Engl J Med 331: 1286
19. Roberts AB, Sporn MB (1993) Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 8: 1
20. Roberts AB, Joyce ME, Bolander ME, Sporn MB (1990) Transforming growth factor-beta (TGF-β): a multifunctional effector of both soft and hard tissue regeneration. In: Westermark B, Betsholtz C, Hökfelt B (eds) Growth factors in health and disease: basic and clinical aspects. Excerpta Medica, Amsterdam, p 89
21. Beck LS, DeGuzman L, Lee WP, Xu Y, Siegel MW, Amento EP (1993) One systemic administration of transforming growth factor-β1 reverses age- or glucocorticoid-impaired wound healing. J Clin Invest 92: 2841
22. Spron MB, Roberts AB (1993) A major advance in the use of growth factors to enhance wound healing. J Clin Invest 92: 2565
23. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL (1993) Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 328: 1592
24. Anscher MS, Murase T, Prescott DM, Marks LB, Reisenbichler H, Bentel GC, Spencer D, Sherouse G, Jirtle RL (1994) Changes in plasma TGFβ levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 30: 671
25. Muir GH, Butta A, Shearer RJ, Fisher C, Dearnaley DP, Flanders KC, Sporn MB, Colletta AA (1994) Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br J Cancer 69: 130
26. Herman M, Katzenellenbogen BS (1994) Alterations in transforming growth factor-α and -β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res 54: 5867
27. Welch DR, Fabra A, Motowo N (1990) Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87: 7678
28. Merzak A, McCrea S, Koocheckpour S, Pilkington GJ (1994) Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor β1. Br J Cancer 70: 199
29. Nakamura T, Tomita Y, Hirai R, Yamaoka K, Kaji K, Ichihara A (1985) Inhibitory effect of transforming growth factor-β on DNA synthesis of adult rat hepatocytes in primary culture. Biochem Biophys Res Commun 133: 1042
30. Carr BI, Hayashi I, Branum EL, Moses HL (1986) Inhibition of DNA synthesis in rat hepatocytes by platelet-derived type β transforming growth factor. Cancer Res 46: 2330
31. Braun L, Mead JE, Panzica M, Mikumo R, Bell GI Fausto N (1988) Transforming growth factor β mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation Proc Natl Acad Sci USA 85: 1539
32. Busso N, Chesne C, Delers F, Morel F, Guillouzo A (1990) Transforming growth-factor-β (TGF-β) inhibits albumin synthesis in normal human hepatocytes and in hepatoma HepG2 cells. Biochem Biophys Res Commun 171: 647
33. Morrone G, Cortese R, Sorrentino V (1989) Post-transcriptional control of negative acute phase genes by transforming growth factor beta. EMBO J 8: 3767
34. Kayanoki Y, Fujii J, Suzuki K, Kawata S, Matsuzawa Y, Taniguchi N (1994) Suppression of antioxidative enzyme expression by transforming growth factor-β1 in rat hepatocytes. J Biol Chem 269: 15488